N. Seidah, S. Benjannet, L. Wickham, J. Marcinkiewicz, S. Jasmin et al., The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation, Proceedings of the National Academy of Sciences, vol.100, issue.3, pp.928-933, 2003.
DOI : 10.1073/pnas.0335507100

P. Costet, M. Krempf, and B. Cariou, PCSK9 and LDL cholesterol: unravelling the target to design the bullet, Trends in Biochemical Sciences, vol.33, issue.9, pp.426-434, 2008.
DOI : 10.1016/j.tibs.2008.06.005

J. Horton, J. Cohen, and H. Hobbs, Molecular biology of PCSK9: its role in LDL metabolism, Trends in Biochemical Sciences, vol.32, issue.2, pp.71-77, 2007.
DOI : 10.1016/j.tibs.2006.12.008

M. Abifadel, M. Varret, J. Rabes, D. Allard, K. Ouguerram et al., Mutations in PCSK9 cause autosomal dominant hypercholesterolemia, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia, pp.154-156, 2003.
DOI : 10.1038/ng1161

J. Cohen, E. Boerwinkle, T. Mosley, . Jr, and H. Hobbs, Low LDL, and Protection against Coronary Heart Disease, New England Journal of Medicine, vol.354, issue.12, pp.1264-1272, 2006.
DOI : 10.1056/NEJMoa054013

R. Giugliano, N. Desai, P. Kohli, W. Rogers, R. Somaratne et al., Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study, The Lancet, vol.380, issue.9858, pp.3802007-2017
DOI : 10.1016/S0140-6736(12)61770-X

E. Stein, D. Gipe, J. Bergeron, D. Gaudet, R. Weiss et al., Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial, The Lancet, vol.380, issue.9836, pp.38029-38065
DOI : 10.1016/S0140-6736(12)60771-5

W. Alborn, G. Cao, H. Careskey, Y. Qian, D. Subramaniam et al., Serum Proprotein Convertase Subtilisin Kexin Type 9 Is Correlated Directly with Serum LDL Cholesterol, Clinical Chemistry, vol.53, issue.10, pp.531814-1819, 2007.
DOI : 10.1373/clinchem.2007.091280

A. Baass, G. Dubuc, M. Tremblay, E. Delvin, J. O-'loughlin et al., Plasma PCSK9 Is Associated with Age, Sex, and Multiple Metabolic Markers in a Population-Based Sample of Children and Adolescents, Clinical Chemistry, vol.55, issue.9, pp.551637-1645, 2009.
DOI : 10.1373/clinchem.2009.126987

G. Dubuc, M. Tremblay, G. Pare, H. Jacques, J. Hamelin et al., A new method for measurement of total plasma PCSK9: clinical applications, The Journal of Lipid Research, vol.51, issue.1, pp.140-149, 2010.
DOI : 10.1194/jlr.M900273-JLR200

S. Lakoski, T. Lagace, J. Cohen, J. Horton, and H. Hobbs, Genetic and Metabolic Determinants of Plasma PCSK9 Levels, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.7, pp.2537-2543, 2009.
DOI : 10.1210/jc.2009-0141

K. Maxwell, R. Soccio, E. Duncan, E. Sehayek, and J. Breslow, Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice, The Journal of Lipid Research, vol.44, issue.11, pp.442109-2119, 2003.
DOI : 10.1194/jlr.M300203-JLR200

G. Dubuc, A. Chamberland, H. Wassef, J. Davignon, N. Seidah et al., Statins Upregulate PCSK9, the Gene Encoding the Proprotein Convertase Neural Apoptosis-Regulated Convertase-1 Implicated in Familial Hypercholesterolemia, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.24, issue.8, pp.241454-1459, 2004.
DOI : 10.1161/01.ATV.0000134621.14315.43

P. Costet, B. Cariou, G. Lambert, F. Lalanne, B. Lardeux et al., Hepatic PCSK9 Expression Is Regulated by Nutritional Status via Insulin and Sterol Regulatory Element-binding Protein 1c, Journal of Biological Chemistry, vol.281, issue.10, pp.2816211-6218, 2006.
DOI : 10.1074/jbc.M508582200

J. Haas, J. Miao, C. D. Wang, Y. Zhao, E. Haas et al., Hepatic Insulin Signaling Is Required for Obesity-Dependent Expression of SREBP-1c mRNA but Not for Feeding-Dependent Expression, Cell Metabolism, vol.15, issue.6, pp.15873-884
DOI : 10.1016/j.cmet.2012.05.002

L. Persson, C. Galman, B. Angelin, and M. Rudling, Importance of Proprotein Convertase Subtilisin/Kexin Type 9 in the Hormonal and Dietary Regulation of Rat Liver Low-Density Lipoprotein Receptors, Endocrinology, vol.150, issue.3, pp.1140-1146, 2009.
DOI : 10.1210/en.2008-1281

J. Browning and J. Horton, Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans, The Journal of Lipid Research, vol.51, issue.11, pp.513359-3363, 2010.
DOI : 10.1194/jlr.P009860

L. Persson, G. Cao, L. Stahle, B. Sjoberg, J. Troutt et al., Circulating Proprotein Convertase Subtilisin Kexin Type 9 Has a Diurnal Rhythm Synchronous With Cholesterol Synthesis and Is Reduced by Fasting in Humans, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.30, issue.12, pp.302666-2672, 2010.
DOI : 10.1161/ATVBAHA.110.214130

C. Richard, P. Couture, S. Desroches, S. Benjannet, N. Seidah et al., Effect of the Mediterranean diet with and without weight loss on surrogate markers of cholesterol homeostasis in men with the metabolic syndrome, British Journal of Nutrition, vol.131, issue.05, pp.1-7, 2011.
DOI : 10.1001/jama.287.5.598

H. Bjermo, D. Iggman, J. Kullberg, I. Dahlman, L. Johansson et al., Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial, American Journal of Clinical Nutrition, vol.95, issue.5, pp.951003-1012
DOI : 10.3945/ajcn.111.030114

B. Guerci, S. Hadjadj, D. Quilliot, O. Ziegler, and P. Drouin, No acute response of leptin to an oral fat load in obese patients and during circadian rhythm in healthy controls, European Journal of Endocrinology, vol.143, issue.5, pp.649-655, 2000.
DOI : 10.1530/eje.0.1430649

B. Cariou, K. Ouguerram, Y. Zair, R. Guerois, C. Langhi et al., PCSK9 Dominant Negative Mutant Results in Increased LDL Catabolic Rate and Familial Hypobetalipoproteinemia, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.29, issue.12, pp.9-292191, 2009.
DOI : 10.1161/ATVBAHA.109.194191

M. Bortolotti, R. Kreis, C. Debard, B. Cariou, D. Faeh et al., High protein intake reduces intrahepatocellular lipid deposition in humans, American Journal of Clinical Nutrition, vol.90, issue.4, pp.1002-1010, 2009.
DOI : 10.3945/ajcn.2008.27296

K. Lê, M. Ith, R. Kreis, D. Faeh, M. Bortolotti et al., Fructose overconsumption causes dyslipidemia and ectopic lipid deposition in healthy subjects with and without a family history of type 2 diabetes, American Journal of Clinical Nutrition, vol.89, issue.6, pp.891760-1765, 2009.
DOI : 10.3945/ajcn.2008.27336

F. Theytaz, Y. Noguchi, L. Egli, V. Campos, T. Buehler et al., Effects of supplementation with essential amino acids on intrahepatic lipid concentrations during fructose overfeeding in humans, American Journal of Clinical Nutrition, vol.96, issue.5, pp.961008-1016
DOI : 10.3945/ajcn.112.035139

B. Lindenthal, T. Aldaghlas, A. Holleran, T. Sudhop, H. Berthold et al., Isotopomer spectral analysis of intermediates of cholesterol synthesis in human subjects and hepatic cells, American Journal of Physiology - Endocrinology And Metabolism, vol.282, issue.6, pp.1222-1230, 2002.
DOI : 10.1152/ajpendo.00324.2001

R. Defronzo, J. Tobin, and R. Andres, Glucose clamp technique: a method for quantifying insulin secretion and resistance, Am J Physiol, vol.237, issue.3, pp.214-223, 1979.

L. May, C. Kourimate, S. Langhi, C. Chetiveaux, M. Jarry et al., Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia, Arterioscler Thromb Vasc Biol, issue.5, pp.29684-690, 2009.

G. Perseghin, S. Ghosh, K. Gerow, and G. Shulman, Metabolic defects in lean nondiabetic offspring of NIDDM parents: a cross-sectional study, pp.1001-1009, 1997.

K. Petersen, S. Dufour, D. Befroy, R. Garcia, and G. Shulman, Impaired Mitochondrial Activity in the Insulin-Resistant Offspring of Patients with Type 2 Diabetes, New England Journal of Medicine, vol.350, issue.7, pp.664-671, 2004.
DOI : 10.1056/NEJMoa031314

J. Warram, B. Martin, A. Krolewski, J. Soeldner, and C. Kahn, Slow Glucose Removal Rate and Hyperinsulinemia Precede the Development of Type II Diabetes in the Offspring of Diabetic Parents, Annals of Internal Medicine, vol.113, issue.12, pp.909-915, 1990.
DOI : 10.7326/0003-4819-113-12-909

A. Borai, C. Livingstone, I. Kaddam, and G. Ferns, Selection of the appropriate method for the assessment of insulin resistance, BMC Medical Research Methodology, vol.63, issue.2, p.158, 2011.
DOI : 10.1006/mgme.1997.2658

K. Ouguerram, M. Chetiveaux, Y. Zair, P. Costet, M. Abifadel et al., Apolipoprotein B100 metabolism in autosomaldominant hypercholesterolemia related to mutations in PCSK9, Arterioscler Thromb Vasc Biol, issue.8, pp.241448-1453, 2004.

G. Lambert, A. Jarnoux, T. Pineau, O. Pape, M. Chetiveaux et al., Fasting induces hyperlipidemia in mice overexpressing PCSK9: lack of modulation of VLDL hepatic output by the LDLr, Endocrinology, issue.10, pp.1474985-4995, 2006.

J. Twisk, D. Gillian-daniel, A. Tebon, L. Wang, and P. Barrett, The role of the LDL receptor in apolipoprotein B secretion, Journal of Clinical Investigation, vol.105, issue.4, pp.521-532, 2000.
DOI : 10.1172/JCI8623

L. Tappy and K. Le, Metabolic Effects of Fructose and the Worldwide Increase in Obesity, Physiological Reviews, vol.90, issue.1, pp.23-46, 2010.
DOI : 10.1152/physrev.00019.2009

Y. Luo, L. Warren, D. Xia, H. Jensen, T. Sand et al., Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice, The Journal of Lipid Research, vol.50, issue.8, pp.501581-1588, 2009.
DOI : 10.1194/jlr.M800542-JLR200

H. Jeong, H. Lee, K. Kim, Y. Kim, D. Yoon et al., Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2, The Journal of Lipid Research, vol.49, issue.2, pp.49399-409, 2007.
DOI : 10.1194/jlr.M700443-JLR200

D. Eberle, B. Hegarty, P. Bossard, P. Ferre, and F. Foufelle, SREBP transcription factors: master regulators of lipid homeostasis, Biochimie, vol.86, issue.11, pp.839-848, 2004.
DOI : 10.1016/j.biochi.2004.09.018

H. Kempen, J. Glatz, G. Leuven, J. Katan, and M. , Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans, J Lipid Res, vol.29, issue.9, pp.1149-1155, 1988.

M. Nissinen, H. Gylling, and T. Miettinen, Responses of surrogate markers of cholesterol absorption and synthesis to changes in cholesterol metabolism during various amounts of fat and cholesterol feeding among healthy men, British Journal of Nutrition, vol.18, issue.02, pp.370-378, 2008.
DOI : 10.1194/jlr.M400167-JLR200

S. Kourimate, M. Le, C. Langhi, A. Jarnoux, K. Ouguerram et al., Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9, Journal of Biological Chemistry, vol.283, issue.15, pp.2839666-9673, 2008.
DOI : 10.1074/jbc.M705831200

M. Wu, B. Dong, A. Cao, H. Li, and J. Liu, Delineation of molecular pathways that regulate hepatic PCSK9 and LDL receptor expression during fasting in normolipidemic hamsters, Atherosclerosis, vol.224, issue.2, pp.401-410
DOI : 10.1016/j.atherosclerosis.2012.08.012

M. Cabezas, T. De-bruin, H. Westerveld, E. Meijer, and D. Erkelens, Delayed chylomicron remnant clearance in subjects with heterozygous familial hypercholesterolaemia, Journal of Internal Medicine, vol.38, issue.4, pp.299-307, 1998.
DOI : 10.1016/0021-9150(94)05430-Q

A. Tremblay, B. Lamarche, I. Ruel, J. Hogue, J. Bergeron et al., Lack of evidence for reduced plasma apo B48 catabolism in patients with heterozygous familial hypercholesterolemia carrying the same null LDL receptor gene mutation, Atherosclerosis, vol.172, issue.2, pp.367-373, 2004.
DOI : 10.1016/j.atherosclerosis.2003.11.011

M. Niesen, M. Bedi, and D. Lopez, Diabetes alters LDL receptor and PCSK9 expression in rat liver, Archives of Biochemistry and Biophysics, vol.470, issue.2, pp.111-115, 2008.
DOI : 10.1016/j.abb.2007.11.009

M. Mbikay, F. Sirois, J. Mayne, G. Wang, A. Chen et al., PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities, FEBS Letters, vol.37, issue.4, pp.701-706, 2009.
DOI : 10.1016/j.febslet.2009.12.018

C. Langhi, L. May, C. Gmyr, V. Vandewalle, B. Kerr-conte et al., PCSK9 is expressed in pancreatic ??-cells and does not alter insulin secretion, Biochemical and Biophysical Research Communications, vol.390, issue.4, pp.1288-1293, 2009.
DOI : 10.1016/j.bbrc.2009.10.138

L. Tappy, K. Le, C. Tran, and N. Paquot, Fructose and metabolic diseases: New findings, new questions, Nutrition, vol.26, issue.11-12, pp.11-121044
DOI : 10.1016/j.nut.2010.02.014

B. Cariou, L. Bras, M. Langhi, C. Le, M. Guyomarc-'h-delasalle et al., Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients, Atherosclerosis, vol.211, issue.2, pp.700-702, 2010.
DOI : 10.1016/j.atherosclerosis.2010.04.015